NCT03248570 2024-11-20Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair DefectsUniversity of California, San FranciscoPhase 2 Completed26 enrolled 18 charts